Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
ABOS
Acumen Pharmaceuticals, Inc.
Sabirnetug is developed as an Alzheimer's disease therapeutic.
|
$132.05M |
$2.04
-6.65%
|
|
ACTU
Actuate Therapeutics Inc
Actuate Therapeutics is a biotech company focused on oncology with a lead product elraglusib (a GSK-3β inhibitor).
|
$131.45M |
$6.54
-2.39%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$129.08M |
$2.83
-0.35%
|
|
IRD
Opus Genetics, Inc.
Core product area: AAV-based gene therapies for inherited retinal diseases (OPGx-LCA5, OPGx-BEST1).
|
$127.67M |
$2.19
+2.10%
|
|
BNR
Burning Rock Biotech Limited
Biopharma services segment indicates outsourced R&D, clinical testing, and development support.
|
$126.56M |
$12.13
-1.06%
|
|
SCLX
Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
|
$124.16M |
$20.23
+13.27%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$123.72M |
$2.37
+10.00%
|
|
VTGN
VistaGen Therapeutics, Inc.
Lead CNS pipeline focused on neuropsychiatric drug development (acute SAD, MDD) and related disorders.
|
$123.63M |
$4.12
-2.95%
|
|
ACNT
Ascent Industries Co.
Custom manufacturing / contract manufacturing services.
|
$120.92M |
$12.03
-0.41%
|
|
IKT
Inhibikase Therapeutics, Inc.
IKT's lead program IKT-001Pro is an oral small-molecule therapeutic prodrug, fitting the 'Oral Small Molecule Therapeutics' investable theme.
|
$118.95M |
$1.65
+2.81%
|
|
XTNT
Xtant Medical Holdings, Inc.
Xtant operates as an OEM/contract manufacturer for orthobiologic and implant products.
|
$113.05M |
$0.83
+2.29%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$111.83M |
$13.34
+2.14%
|
|
ATOS
Atossa Therapeutics, Inc.
Atossa is a clinical-stage biotech focused on oncology with Z-endoxifen as its lead cancer therapy candidate.
|
$111.51M |
$0.85
-1.48%
|
|
AGEN
Agenus Inc.
Agenus' core focus is oncology with immunotherapy approaches (BOT/BAL) in MSS CRC, supporting Biotech - Oncology.
|
$108.84M |
$3.75
-5.54%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell off-the-shelf T cell therapies and the TVGN 489 program position Tevogen as a cell therapy biotech focused on oncology and infectious disease.
|
$108.15M |
$0.56
-4.20%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$107.61M |
$11.18
-6.68%
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$106.93M |
$15.68
-3.83%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
ANEB
Anebulo Pharmaceuticals, Inc.
Anebulo's lead candidate selonabant is a small molecule therapeutic (initially oral) targeting cannabis-induced CNS effects; thus aligns with Oral Small Molecule Therapeutics.
|
$104.36M |
$2.55
+0.39%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis is a biotech company focused on oncology therapies, centered on cancer indications with their lead asset azenosertib.
|
$103.61M |
$1.34
-6.60%
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$102.52M |
$1.60
-3.89%
|
|
NIKA
Nika Pharmaceuticals Inc.
ITV-1 HIV therapeutic concept and related immunomodulatory platform sit within Biotech - Immunology Therapeutics.
|
$102.15M |
$0.30
|
|
CGTX
Cognition Therapeutics, Inc.
CT1812 (zervimesine) is an orally delivered small-molecule therapeutic, the core product of the company.
|
$101.67M |
$1.57
-3.96%
|
|
IMMX
Immix Biopharma, Inc.
Directly categorizes the company’s lead product as a CAR-T cell therapy (cell therapy).
|
$101.47M |
$3.50
-3.85%
|
|
COYA
Coya Therapeutics, Inc.
COYA's autologous regulatory T cell therapy program (COYA 101) represents a direct cell therapy product line.
|
$100.35M |
$5.94
-1.00%
|
|
RCEL
AVITA Medical, Inc.
RECELL/autologous cell suspension represents a cell-therapy platform within regenerative medicine.
|
$99.92M |
$3.79
+0.13%
|
|
MGNX
MacroGenics, Inc.
Company develops bispecific antibody therapies via its DART platform, including lorigerlimab.
|
$99.68M |
$1.45
-8.23%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's lead candidate etripamil is a cardiovascular drug developed for PSVT and AFib-RVR.
|
$98.91M |
$1.85
|
|
SLGL
Sol-Gel Technologies Ltd.
SGT-610 and SGT-210 target rare dermatologic diseases (Gorlin syndrome, Darier disease), aligning with the Rare Diseases investable theme.
|
$98.89M |
$33.95
-4.37%
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$96.88M |
$1.11
+2.78%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$96.41M |
$2.29
-3.18%
|
|
KBLB
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories produces recombinant spider silk proteins via transgenic silkworms, a core product category defined as Recombinant Proteins & Enzymes.
|
$96.23M |
$0.09
|
|
STTK
Shattuck Labs, Inc.
SL-325 is a monoclonal antibody targeting DR3, making Monoclonal Antibody Therapeutics a direct product category.
|
$95.32M |
$1.98
-0.75%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$94.79M |
$1.51
-5.63%
|
|
CSBR
Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
|
$93.68M |
$6.76
-0.59%
|
|
STRO
Sutro Biopharma, Inc.
Directly represents Sutro's core assets: Antibody-Drug Conjugates (ADC) programs using the XpressCF+ platform.
|
$92.91M |
$1.04
-5.00%
|
Showing page 16 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
